Oncology firm Immunome's Q2 net loss widens as R&D costs rise
IMNM•Cash position and development outlook
The company ended the second quarter with $520 million in cash and marketable securities and expects that balance to fund operations into 2028.
Immunome expects to submit a European Union Marketing Authorization Application for varegacestat by the end of 2026. The FDA PDUFA target action date for varegacestat is set for April 28, 2027.
Quarterly result and analyst backdrop
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 loss per share | $0.65 |
The current average analyst rating on the shares is buy, with 14 strong buy or buy recommendations, no hold ratings and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology and medical research peer group is buy. Wall Street's median 12-month price target for Immunome, Inc. is $35.50, about 38.2% above its Aug. 10 closing price of $25.69.
